PSA筛查获益新证据:40万Kaiser Permanente患者数据
该回顾性队列纳入400,887名80岁以下、无前列腺癌史的男性,按筛查间隔和年龄分层,随访12-16年。结果显示55-75岁男性每年PSA筛查使前列腺癌死亡降低64%(95%CI 50-78%,P<.001),全因死亡降低24%(95%CI 15-34%,P<.001);55岁以下任何间隔筛查均无获益。
要点
- 55-75岁男性每年PSA筛查可显著降低前列腺癌死亡和全因死亡。
- 55岁以下男性在任何筛查间隔下均未观察到获益。
- 每年筛查为优选间隔,结合主动监测可减少过度治疗。
核心结论
- 每年PSA筛查可高效降低前列腺癌死亡和全因死亡,支持55-75岁健康状况良好男性进行筛查。
- 55岁以下男性在任何筛查间隔下均无获益。
研究设计与样本
- 回顾性队列研究,纳入400,887名80岁以下、无前列腺癌史且在1998-2002年5个日历年内于Kaiser Permanente Northern California接受PSA检测的男性。
- 随访12-16年,按筛查间隔分为6组、按年龄分为7组,共42个亚组比较前列腺癌死亡率。
主要发现
- 55-75岁男性每年PSA筛查使前列腺癌死亡降低64%(95%CI 50-78%,P<.001)。
- 55-75岁男性每年PSA筛查使全因死亡降低24%(95%CI 15-34%,P<.001)。
- 55岁以下男性在任何筛查间隔下均未发现获益。
- 每年筛查为优选间隔。
关键数值与推荐
- 推荐55-75岁健康状况良好男性每年进行PSA筛查。
- 55岁以下男性不推荐任何间隔的PSA筛查。
- 筛查需结合主动监测以防止过度治疗。
临床怎么用
- 对55-75岁健康状况良好的男性,可建议每年PSA筛查并说明其降低前列腺癌死亡和全因死亡的获益。
- 对55岁以下男性,不应常规推荐PSA筛查。
- 筛查阳性后应结合主动监测策略,减少过度治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether prostate cancer screening with prostate-specific antigen (PSA) is beneficial in reducing prostate cancer mortality, and to determine optimal screening intervals and age groups to be screened. METHODS: This is a retrospective cohort study of 400,887 men under age 80, with no history of prostate cancer, who had PSA testing at Kaiser Permanente Northern California in the 5 calendar years 1998-2002, and were followed up for 12-16 years. Subjects were stratified into 6 groups based on the screening interval, and into 7 groups based on age. Prostate cancer mortality rates for each of the 42 subgroups were calculated and compared. RESULTS: The data show that yearly PSA screening is beneficial, reducing prostate cancer deaths by 64% for men aged 55-75 years (95% confidence interval 50-78%, P <.001), and all-cause mortality by 24% (95% confidence interval 15%-34%, P <.001). This is the first study to evaluate various screening intervals and age groups, showing that yearly screening is the interval of choice. No benefit was found for screening at any interval for men under age 55. CONCLUSION: Yearly PSA screening is highly effective in reducing both prostate cancer mortality and all-cause mortality in men with prostate cancer, and when combined with active surveillance to prevent overtreatment, lends support for PSA screening for men in good health aged 55-75.
引用
- Alpert PF. New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients. Urology. 2018. PMID: 29772218. doi:10.1016/j.urology.2018.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。